Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$19.98 USD
-0.28 (-1.38%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $19.97 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 681 - 700 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Initiation of First of Two EXPAREL Pivotal Nerve Block Trials Sets Timeline For Potential Q4:13 or Q1:14 sNDA Filing; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $23 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 16
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Solid Momentum Behind EXPAREL Launch While Nerve Block Indication Provides Long-Term Value, In Our View.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
September and Remaining 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EMA Concerns Regarding DepoCyte Manufacturing Not Material, In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $18 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 EXPAREL Sales Beat as Launch Off to Very Promising Start; Reiterate OUTPERFORM and $18 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
June Wolters Kluwer Data for EXPAREL. Reiterate OUTPERFORM and $18 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
May Wolters Kluwer Data for EXPAREL Suggests Solid Second Month of Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Health Economics Data Provides Compelling Marketing Tool for Exparel, In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
April Wolters Kluwer Data for EXPAREL; Reiterate OUTPERFORM and $15 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Financials: We Believe April EXPAREL Sales Suggest Solid Start to Launch. Reiterate OUTPERFORM and $15 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We Estimate Financing Extends Cash Runway Into Potential Profitability - Reiterate OUTPERFORM, FV Lowered to $15
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Now Commercially Available-We Believe Groundwork Laid for a Successful aunch-Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L